Literature DB >> 12869693

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Igor M Belyakov1, Patricia Earl, Amiran Dzutsev, Vladimir A Kuznetsov, Michael Lemon, Linda S Wyatt, James T Snyder, Jeffrey D Ahlers, Genoveffa Franchini, Bernard Moss, Jay A Berzofsky.   

Abstract

The concern about bioterrorism with smallpox has raised the possibility of widespread vaccination, but the greater prevalence of immunocompromised individuals today requires a safer vaccine, and the mechanisms of protection are not well understood. Here we show that, at sufficient doses, the protection provided by both modified vaccinia Ankara and NYVAC replication-deficient vaccinia viruses, safe in immunocompromised animals, was equivalent to that of the licensed Wyeth vaccine strain against a pathogenic vaccinia virus intranasal challenge of mice. A similar variety and pattern of immune responses were involved in protection induced by modified vaccinia Ankara and Wyeth viruses. For both, antibody was essential to protect against disease, whereas neither effector CD4+ nor CD8+ T cells were necessary or sufficient. However, in the absence of antibody, T cells were necessary and sufficient for survival and recovery. Also, T cells played a greater role in control of sublethal infection in unimmunized animals. These properties, shared with the existing smallpox vaccine, provide a basis for further evaluation of these replication-deficient vaccinia viruses as safer vaccines against smallpox or against complications from vaccinia virus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869693      PMCID: PMC170940          DOI: 10.1073/pnas.1233578100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL.

Authors:  I M Belyakov; J D Ahlers; J D Clements; W Strober; J A Berzofsky
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

2.  Bioterrorism: a clear and present danger.

Authors:  H C Lane; J L Montagne; A S Fauci
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

Review 3.  Strategies for designing and optimizing new generation vaccines.

Authors:  J A Berzofsky; J D Ahlers; I M Belyakov
Journal:  Nat Rev Immunol       Date:  2001-12       Impact factor: 53.106

4.  DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.

Authors:  J W Hooper; D M Custer; C S Schmaljohn; A L Schmaljohn
Journal:  Virology       Date:  2000-01-20       Impact factor: 3.616

5.  Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo.

Authors:  C L Lin; C S Chung; H G Heine; W Chang
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.

Authors:  I M Belyakov; Z Hel; B Kelsall; V A Kuznetsov; J D Ahlers; J Nacsa; D I Watkins; T M Allen; A Sette; J Altman; R Woodward; P D Markham; J D Clements; G Franchini; W Strober; J A Berzofsky
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

Review 7.  Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections.

Authors:  J A Berzofsky; J D Ahlers; M A Derby; C D Pendleton; T Arichi; I M Belyakov
Journal:  Immunol Rev       Date:  1999-08       Impact factor: 12.988

8.  Th cell-deficient mice control influenza virus infection more effectively than Th- and B cell-deficient mice: evidence for a Th-independent contribution by B cells to virus clearance.

Authors:  K Mozdzanowska; K Maiese; W Gerhard
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

9.  Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus.

Authors:  G Sutter; B Moss
Journal:  Dev Biol Stand       Date:  1995

10.  Developing new smallpox vaccines.

Authors:  S R Rosenthal; M Merchlinsky; C Kleppinger; K L Goldenthal
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

View more
  134 in total

1.  Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells.

Authors:  Rama Rao Amara; Pragati Nigam; Sunita Sharma; Jinyan Liu; Vanda Bostik
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

2.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 3.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 4.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

5.  The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice.

Authors:  Shahram Salek-Ardakani; Rachel Flynn; Ramon Arens; Hideo Yagita; Geoffrey L Smith; Jannie Borst; Stephen P Schoenberger; Michael Croft
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

6.  Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.

Authors:  Shawn S Jackson; Petr Ilyinskii; Valérie Philippon; Linda Gritz; Alicia Gómez Yafal; Kimberly Zinnack; Kristin R Beaudry; Kelledy H Manson; Michelle A Lifton; Marcelo J Kuroda; Norman L Letvin; Gail P Mazzara; Dennis L Panicali
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Characterization of murine antibody responses to vaccinia virus envelope protein A14 reveals an immunodominant antigen lacking of effective neutralization targets.

Authors:  Xiangzhi Meng; Thomas Kaever; Bo Yan; Paula Traktman; Dirk M Zajonc; Bjoern Peters; Shane Crotty; Yan Xiang
Journal:  Virology       Date:  2018-03-17       Impact factor: 3.616

8.  Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry.

Authors:  Markus Cornberg; Brian S Sheridan; Frances M Saccoccio; Michael A Brehm; Liisa K Selin
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

9.  Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination.

Authors:  Garilyn M Jentarra; Michael C Heck; Jin Won Youn; Karen Kibler; Jeffrey O Langland; Carole R Baskin; Olga Ananieva; Yung Chang; Bertram L Jacobs
Journal:  Vaccine       Date:  2008-04-08       Impact factor: 3.641

10.  Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Authors:  Cassandra L Braxton; Shelby H Puckett; Steven B Mizel; Douglas S Lyles
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.